CA
AMBI

Commerzbank Aktiengesellschaft’s Ambit Biosciences Corp AMBI Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio AMBI Stock Details AMBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-71,000
Closed -$648K – 1268
2014
Q1 		$648K Buy
+71,000
New +$753K ﹤0.01% 920

Other funds holding AMBI

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commerzbank Aktiengesellschaft's AMBI Position: Q2 2014 in Review

Commerzbank Aktiengesellschaft sold out of Ambit Biosciences Corp (AMBI) in Q2 2014, closing a stake of 71,000 shares — an estimated $648K sold.

Commerzbank Aktiengesellschaft first reported a position in AMBI in Q1 2014 and held it in 1 quarter. The position peaked at $648K in Q1 2014. 36 funds tracked by Wall St. Rank hold AMBI as of Q2 2014.

  • Commerzbank Aktiengesellschaft reported no remaining Ambit Biosciences Corp position as of Q2 2014 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 71,000 Ambit Biosciences Corp shares in Q2 2014, an estimated $648K.
  • Commerzbank Aktiengesellschaft first reported a position in Ambit Biosciences Corp in Q1 2014 and held it in 1 quarter.
  • Commerzbank Aktiengesellschaft's Ambit Biosciences Corp position peaked at $648K in Q1 2014.
  • 36 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q2 2014.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2014, filed 12 Aug 2014.